The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia

Atherosclerosis

Volumn 143, Issue 1, 1999, Pages 41-54

  Heath, Karen E ^a,b   Gudnason, Vilmundur ^a   Humphries, Steve E ^a   Seed, Mary ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Cholesterol; Familial hypercholesterolaemia (FH); LDLR mutation; Simvastatin; Tendon xanthoma (TX)

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN E; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SIMVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; FAMILIAL DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 2; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; APOLIPOPROTEINS E; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUSCULAR DISEASES; MUTATION; RECEPTORS, LDL; SIMVASTATIN; TENDONS; XANTHOMATOSIS;

EID: 0032993468     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00274-3     Document Type: Article

References (49)

1. Hobbs HH, Brown MS, Goldstein JL Molecular genetics of the LDL-receptor gene in familial hypercholesterolaemia. Hum Mut. 1:1992;445-466.
2. Day INM, Whittall RA, O'Dell SD, Haddad L, Bolla MK, Gudnason V, Humphries SE Spectrum of LDL-receptor gene mutations in heterozygous familial hypercholesterolaemia. Hum Mut. 10:1997;116-127.
3. Wilson DJ, Gahan M, Haddad L, Heath K, Whittall RA, Williams RR, Humphries SE, Day INM A world wide web site for LDL-receptor gene mutations in familial hypercholesterolaemia: sequence based, tabular and direct submission data handling. Am J Cardiology. 81:1998;1509-1511.
4. Sun X-M, Neuwirth C, Patel DD, Knight BL, Soutar AK Comparison of the genetic defect with LDL-receptor activity in cultured cells from patients with a clinical diagnosis of heterozygous familial hypercholesterolaemia. Arterioscler Thromb Vasc Biol. 17:1997;3092-3101.
5. Tybjaerg-Hansen A, Gallagher J, Vincent J, Houlston R, Talmud P, Dunning AM, Seed M, Hamsten A, Humphries SE, Myant NB Familial defective apolipoprotein B-100: Detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis. 80:1990;235-242.
6. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolaemia. J Lipid Res. 31:1990;1337-1349.
7. Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, Landsberger D, Sehayek E, Wurm M, Bard J-M, Fruchart J-C, Stein Y Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolaemia. Circulation. 87(4, Suppl. III):1993;35-44.
8. Jeenah M, September W, Graadt vam Roggen F, de Villiers W, Seftel H, Marais D Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia. Atherosclerosis. 98(1):1993;51-58.
9. th International Symposium on Atherosclerosis 1997;134:54.
10. Kajinami K, Yagi K, Higashikata T, Inazu J, Koizumi H, Mabuchi H Low density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolaemia. Am J Cardiol. 82:1998;113-117.
11. Sijbrands EJG, Lombardi MP, Westendorp RGJ, Gevers Leuven JAG, Meinders AE, Vand der Laarse A, Frants RR, Havekes LM, Smelt AHM. Similar response to simvastatin in patients heterozygous for familial hypercholesterolaemia with mRNA negative and mRNA postive mutations. Atherosclerosis 1998; 247-254.
12. Sun X-M, Neuwirth C, Patel DD, Knight BL, Soutar AK with the Familial hypercholesterolaemia regression study group. Influence of genotpe at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. Atherosclerosis. 136:1998;175-185.
13. Grundy SM HMG-CoA reductase inhibitors for treatment of hypercholesterolaemia. N Eng J Med. 3:1998;24-33.
14. Pyorala K, De-Backer G, Graham I, Poole-Wilson P, Wood D Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society of Hypertension. Atherosclerosis. 110(2):1994;121-161.
15. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ. 303:1991;893-896.
16. Burstein M, Schlonick HR, Morfin R Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 11:1970;583-595.
17. Labeur C, Rosseneu M, Henderson LO. Results of two international surveys on Lp(a) measurements. New Orleans 1992;83.
18. Friedewald WT, Levy RI, Fredrickson DS Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
19. Nicolaides NC, Stoeckert CJ A simple, efficient method for the separate isolation of RNA and DNA from the same cells. Biotechniques. 8(2):1990;154-156.
20. Whittall R, Gudnason V, Weavind GP, Day LB, Humphries SE, Day INM Utilities for high throughput use of the single strand conformational polymorphism method: screening of 791 patients with familial hypercholesterolaemia for mutations in exon 3 of the low density lipoprotein receptor gene. J Med Genet. 322:1995;509-515.
21. Day IN, Humphries SE, Richards S, Norton D, Reid M High-throughput genotyping using horizontal polyacrylamide gels with wells arranged for microplate array diagonal gel electrophoresis (MADGE). Biotechniques. 19(5):1995;830-835.
22. Mamotte CDS, van Bockxmeer FM A robust strategy for screening and confirmation of familial defective apolipoprotein B100. Clin Chem. 39(1):1993;118-121.
23. Pullinger CR, Hennessy LK, Chatterton JE, Weiqun L, Love JA, Mendel CM, Frost PH, Malloy MJ, Schumaker VN, Kane JP Familial ligand-defective apolipoprotein B: identification of a new mutation that decreases LDL-receptor binding activity. J Clin Invest. 95:1995;1225-1234.
24. Gaffney D, Reid JM, Cameron IM, Cass L, Caslake MJ, Shepherd J, Packard CJ Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidaemia. Arterioscler Thromb Vasc Biol. 15:1995;1025-1029.
25. Bolla MK, Haddad L, Humphries SE, Winder AF, Day IN High-throughput method for determination of apolipoprotein E genotypes with use of restriction digestion analysis by microplate array diagonal gel electrophoresis. Clin Chem. 41(11):1995;1599-1604.
26. Henry JA, Bolla M, Osmond C, Fall C, Barker DJP, Humphries SE The effects of genotype and infant weight on adult plasma levels of fibriniogen, factor VII, and LDL-cholesterol are additive. J Med Genet. 34:1997;553-558.
27. Gudnason V, King-Underwood L, Seed M, Sun X-M, Soutar AK, Humphries SE Identification of recurrent and novel mutations in exon 4 of the LDL-receptor gene in patients with familial hypercholesterolaemia in the United Kingdom. Arterioscler Thromb. 13:1993;56-63.
28. Thompson GR, Maher VM, Matthews S, Kitano Y, Neuwirth C, Short MB, Davies G, Rees A, Mir A, Prescott RJ et al. Familial hypercholesterolaemia regression study: a randomised trial of low density lipoprotein apheresis. Lancet. 345(8953):1995;811-816.
29. Jackson G Statins and coronary heart disease - its the end points that count. British J Clin Practice. 51:1997;2.
30. Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CKY, Thompson GR Decreased production of LDL-cholesterol by atorvastatin after apheresis in homozygous familial hypercholesterolaemia. J Lipid Res. 38:1997;2071-2078.
31. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM Reduction of LDL-cholesterol by 25% to 60% in parients with primary hypercholesterolaemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15:1995;678-682.
32. Jones P, Kafonek S, Laurora L, Hunninghake D Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolaemia. Am J Cardiol. 81(5):1998;582-587.
33. Thompson GR What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis. 131:1997;1-5.
34. Vaughan CJ, Murphy MB, Buckley BM Statins do more than just lower cholesterol. Lancet. 348(9034):1996;1079-1082.
35. Steering committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1998: in press.
36. Assmann G, Schulte H, Cullen P New and classical risk factors - the Munster heart study (PROCAM). Eur J Med Res. 2(6):1997;237-242.
37. Sing CF, Davignon J Role of apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 37:1985;268-285.
38. Duly EB, Ward AJ, Kirk CW, Nevin NC, Trinick TR, Nicholls DP, Young IS, Graham CA APOE genotype and familial hypercholesterolaemia. Ann Clin Biochem. 34:1997;534-536.
39. O'Malley JP, Illingworth DR The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolaemia. Metabolism. 39(2):1990;150-154.
40. De Knijff P, Stalenhoef AFH, Mol MJTM, Gevers Leivem JA, Smit J, Erkelens DW, Schouten J, Frants RR, Havekes LM Influence of apoE polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis. 63:1990;89-97.
41. Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J The response to lovastatin treatment in patients with heterozygous familial hypercholesterolaemia is modulated by apolipoprotein E polymorphism. Metabolism. 42(7):1993;895-901.
42. Lestavel-Delattre S, Benhamamouch S, Agnami G, Luc G, Bard JM, Brousseay T, Billardon C, Kusnierz JP, De Gennes JL, Fruchart JC, Clavey Evidence of non-deficient low density lipoprotein receptor patients in a pool of subjects with clinical familial hypercholesterolaemia profile. Metabolism. 43(4):1994;397-402.
43. Day INM, Haddad L, O'Dell S, Day LB, Whittall RA, Humphries SE. Identification of a common low density lipoprotein receptor mutation (R329X) in the south of England: complete linkage disequilibrium with an allele of microsatellite D19S394. J Med Genet. 34:1997;111-116.
44. Haddad L, Day LB, Attwood A, Povey S, Humphries SE, Day INM Development of a microsatellite-based approach to co-segregation analysis of familial hypercholesterolaemic kindreds. Ann Hum Gen. 61:1997.
45. Haddad L, Day INM, Williams RR, Humphries SE, Hopkins PN. Evidence for a third genetic locus causing familial hypocholesterolaemia: a non-LDLR, non-APOB kindred. J. Lipid Res.: submitted.
46. Gudnason V, Day INM, Humphries SE Effect on plasma lipid levels of different classes of mutations in the low density lipoprotein receptor gene in patients with familial hypercholesterolaemia. Arterioscler Thromb. 14:1994;1717-1721.
47. Leonard JV, Whitelaw AG, Wolff OH, Lloyd JK, Slack J Diagnosing familial hypercholesterolaemia in childhood by measuring serum cholesterol. BMJ. 1(6076):1977;1566-1568.
48. Kessling AM, Seed M, Taylor R, Wynn V, Humphries SE Rising cholesterol levels in children with familial hypercholesterolaemia. Biomed Pharmacother. 44(7):1990;373-379.
49. Humphries SE, Galton D, Nicholls P Genetic testing for familial hypercholesterolaemia: practical and ethical issues. Quart J Med. 90(3):1997;169-181.